Questionnaires on health-related quality of life (HRQoL) play a crucial role in managing patients by revealing insights into physical, psychological, lifestyle, and social factors affecting well-being. A methodological aspect that has not been adequately explored yet, and is of considerable potential, is causal discovery. This study explored causal discovery techniques within HRQoL, assessed various considerations for reliable estimation, and proposed means for interpreting outcomes. Five causal structure learning algorithms were employed to examine different aspects in structure estimation based on simulated data derived from HRQoL-related directed acyclic graphs. The performance of the algorithms was assessed based on various measures related to the differences between the true and estimated structures. Moreover, the Resource Description Framework was adopted to represent the responses to the HRQoL questionnaires and the detected cause–effect relationships among the questions, resulting in semantic knowledge graphs which are structured representations of interconnected information. It was found that the structure estimation was impacted negatively by the structure’s complexity and favorably by increasing the sample size. The performance of the algorithms over increasing sample size exhibited a similar pattern, with distinct differences being observed for small samples. This study illustrates the dynamics of causal discovery in HRQoL-related research, highlights aspects that should be addressed in estimation, and fosters the shareability and interoperability of the output based on globally established standards. Thus, it provides critical insights in this context, further promoting the critical role of HRQoL questionnaires in advancing patient-centered care and management.
Azacytidine is the only approved treatment for patients with higher-risk myelodysplastic syndromes (MDS); yet less than half of the patients will achieve a response, whereas the duration of response is highly heterogeneous and there are no predictors for response duration. The aim of this study is to estimate the patient’s time to loss of response (LoR) to azacytidine based on clinical measurements during treatment. To this end, a personalized prediction framework is proposed that estimates the LoR of a new patient using a patient similarity-based approach. Namely, the new patient’s clinical data—represented as a multivariate time series—are compared to a reference set of patients. The comparison uses distance metrics that quantify how similar two patients’ time series are, assuming patients with similar trajectories tend to have similar LoR. Then, the LoR of the new patient is predicted by averaging the outcomes of the most similar reference patients. The pipeline includes a data normalization strategy that centers each feature on its baseline value and scales it to highlight relative changes and distance metrics to quantify similarity. Both real-world and simulated data were utilized to evaluate the proposed methodology, employing the leave-one-out validation and the Mean Absolute Percentage Error (MAPE) to assess accuracy. The estimated MAPE was found to be 30.52% and 11.82% in the real-world and simulated dataset, respectively. The best and most robust predictions were achieved using the Euclidean distance metric and setting the number of most similar patients around three to five. This study proposes a personalized predictive approach for the LoR to azacitidine in the MDS clinical setting, demonstrating potential for a serviceable prediction of LoR and forming the foundation for further research.